CH-St. Gallen-KSSG

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia4 trials
• Myelodysplastic syndromes3 trials
• Multiple myeloma1 trial

Phase

• Phase 34 trials
• Phase 21 trial

Status

• Active, not recruiting3 trials
• Completed1 trial
• Recruiting1 trial

Lead sponsor

• Stichting Hemato-Oncologie voor Volwassenen Nederland5 trials

Running trials

• Recruiting

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

  Contact: M. Schittenhelm

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients

  NCT04097470· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

  NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting

Closed trials

• Completed

  Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

  NCT01208766· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source